Terms: = Prostate cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Prognosis
2305 results:
1. A cross-sectional study of ERG expression and the relationship with clinicopathological features of prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract] [Full Text] [Related]
2. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of Treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
3. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
4. Role of antihypertensive medicines in prostate cancer: a systematic review.
Iheanacho CO; Enechukwu OH
BMC Cancer; 2024 Apr; 24(1):542. PubMed ID: 38684963
[TBL] [Abstract] [Full Text] [Related]
5. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
6. Parathyroid hormone related-protein (PTHrP) in tissues with poor prognosis in prostate cancer patients.
Zhao Y; Lu SM; Zhong B; Wang GC; Jia RP; Wang Q; Long JH
Medicine (Baltimore); 2024 Apr; 103(17):e37934. PubMed ID: 38669432
[TBL] [Abstract] [Full Text] [Related]
7. Mechanism of single-stranded DNA annealing by RAD52-RPA complex.
Liang CC; Greenhough LA; Masino L; Maslen S; Bajrami I; Tuppi M; Skehel M; Taylor IA; West SC
Nature; 2024 May; 629(8012):697-703. PubMed ID: 38658755
[TBL] [Abstract] [Full Text] [Related]
8. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
[TBL] [Abstract] [Full Text] [Related]
9. Risk factor analysis and nomogram construction in patients with distant metastatic prostate cancer at different PSA levels: a study based on the SEER database.
Li HD; Fan SQ; Qin F; Zhao ST; Kong SP; Ma JG
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2372-2386. PubMed ID: 38567600
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract] [Full Text] [Related]
11. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
12. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
[TBL] [Abstract] [Full Text] [Related]
13. [Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy（2024 edition）].
Chinese Prostate Cancer Consortium
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(0):285-295. PubMed ID: 38527740
[TBL] [Abstract] [Full Text] [Related]
14. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
15. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
16. [Role of Bone Scan Index (BSI) in the prognosis and Treatment Efficacy in Castration-Sensitive prostate cancer Patients with Bone Metastasis].
Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
[TBL] [Abstract] [Full Text] [Related]
17. Development of Novel Models of Aggressive Variants of Castration-resistant prostate cancer.
Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
[TBL] [Abstract] [Full Text] [Related]
18. A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
Chen J; Yu F; He G; Hao W; Hu W
BMC Cancer; 2024 Feb; 24(1):254. PubMed ID: 38395827
[TBL] [Abstract] [Full Text] [Related]
19. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract] [Full Text] [Related]
20. Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Incesu RB; Barletta F; Tappero S; Piccinelli ML; Garcia CC; Morra S; Scheipner L; Tian Z; Saad F; Shariat SF; Ahyai S; Longo N; Chun FKH; de Cobelli O; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Cancer Epidemiol; 2024 Apr; 89():102538. PubMed ID: 38377946
[TBL] [Abstract] [Full Text] [Related]
[Next]
